Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics develops and commercializes therapies for B-cell diseases, with news centered on BRIUMVI (ublituximab-xiiy), its anti-CD20 monoclonal antibody for adult patients with relapsing forms of multiple sclerosis. Company updates commonly cover U.S. net product revenue, global revenue targets, commercial demand, and international commercialization economics tied to BRIUMVI.
Recurring developments also include clinical and real-world data for BRIUMVI in relapsing multiple sclerosis, presentations and publications from multiple sclerosis studies, and development work on a subcutaneous formulation. Corporate news includes financing arrangements, share repurchase authorization updates, operating-expense guidance, and business outlook commentary alongside quarterly and annual results.
Precision BioSciences (Nasdaq: DTIL) reported Q2 2026 results and a business update, highlighting first clinical biopsy evidence from the Phase 1 ELIMINATE-B trial that PBGENE-HBV directly reduces hepatitis B cccDNA. A patient showed a 1-log reduction with <1% cccDNA remaining after two 0.4 mg/kg doses, and repeat dosing in another patient increased anti-cccDNA effect. pgRNA became durably undetectable in 100% of evaluable patients, with substantial S-antigen declines across all dose levels and no dose-limiting toxicities in 16 patients.
PBGENE-DMD advanced with two active Phase 1/2 FUNCTION-DMD trial sites now recruiting, and initial safety data targeted for year-end 2026. Cash, cash equivalents and restricted cash were $112.4 million at June 30, 2026, which Precision expects to fund operations and PBGENE-HBV and PBGENE-DMD data milestones through 2028. Q2 2026 R&D expenses were $12.4 million, G&A $6.8 million, and net loss was $32.7 million, including $13.5 million of other expense driven primarily by non-cash warrant liability revaluation.
TG Therapeutics (NASDAQ:TGTX) reported second quarter 2026 total global revenue of $240.3 million, including U.S. BRIUMVI net product revenue of $227.7 million, up about 64% year over year. Net product revenue reached $235.8 million, while license, milestone, royalty and other revenue was $4.5 million.
R&D expense rose to $95.3 million and SG&A to $82.1 million, driven by subcutaneous BRIUMVI manufacturing, secondary manufacturer start-up and commercialization costs. Net income was $7.8 million, and cash, cash equivalents and investment securities totaled $612.3 million at June 30, 2026.
The company raised full-year 2026 total global revenue guidance to ~$950 million and BRIUMVI U.S. net product revenue guidance to $890–$905 million, and guided operating expenses (R&D plus SG&A) to $350–$400 million, plus about $100 million in subcutaneous BRIUMVI manufacturing and secondary manufacturer costs. TG Therapeutics highlighted positive Phase 3 ENHANCE data supporting a single 600 mg initiation infusion for BRIUMVI in RMS, encouraging Phase 1 subcutaneous BRIUMVI data, and progress in myasthenia gravis, schizophrenia, and its azer-cel cell therapy program.
TG Therapeutics (NASDAQ:TGTX) will host a conference call on Monday, August 3, 2026 at 8:30 AM ET to discuss its second quarter 2026 financial results and provide a business outlook for the remainder of 2026, led by Chairman and CEO Michael S. Weiss.
Investors can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (international), using the conference title “TG Therapeutics Earnings Call,” or via live webcast on the Events page in the Investors & Media section of the company’s website. An audio replay will be available online for 30 days, and financial results will be released in a press statement prior to the call.
TG Therapeutics (NASDAQ:TGTX) has started a Phase 2, open-label, single-arm, multicenter trial of BRIUMVI (ublituximab-xiiy) in about 60 adults with treatment-resistant schizophrenia.
Participants receive intravenous BRIUMVI plus standard antipsychotics. The primary endpoint is ≥20% PANSS total score reduction at Week 12.
TG Therapeutics (NASDAQ:TGTX) reported positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis (MG) and started a potentially registration-directed randomized Phase 2 trial.
In Phase 1 (n=11), 82% achieved MG-ADL MCID with a mean 4.6-point improvement; BRIUMVI was generally well tolerated.
TG Therapeutics (NASDAQ:TGTX) reported positive Phase 1 results for a high‑concentration subcutaneous formulation of BRIUMVI (ublituximab-xiiy) for multiple sclerosis.
PK/PD data and modeling suggest quarterly and every‑other‑month subcutaneous dosing can achieve non‑inferior 24‑week drug exposure versus IV BRIUMVI, with mean bioavailability >60% and no new safety signals.
More than 100 patients received treatment, with >225 subcutaneous injections. Subcutaneous dosing showed B‑cell depletion consistent with IV BRIUMVI and was generally well tolerated, supporting the 400 mg/2 mL quarterly regimen now under evaluation in a fully enrolled Phase 3 trial, with top‑line data expected around late 2026 to early 2027.
TG Therapeutics (NASDAQ:TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the Goldman Sachs 47th Annual Healthcare Conference at the Loews Miami Beach Hotel in Florida from June 8-10, 2026.
A fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 PM ET, with a live webcast available on the Events page in the Investors & Media section of the company website.
TG Therapeutics (NASDAQ:TGTX) reported post-hoc pooled data from Phase 3 ULTIMATE I & II trials of BRIUMVI (ublituximab) in treatment-naive adults with relapsing multiple sclerosis over 96 weeks.
Ublituximab cut annualized relapse rate by 56.7% vs teriflunomide, sharply reduced MRI lesions, and achieved NEDA-3 in 82.7% of patients vs 23.1% on teriflunomide, with greater confirmed disability improvement, including in those treated within three years of symptom onset.
TG Therapeutics (NASDAQ:TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City, June 2-4, 2026.
A fireside chat is scheduled for Wednesday, June 3, 2026, at 11:40 AM ET, with a live webcast available on the company’s investor website Events page.
TG Therapeutics (NASDAQ:TGTX) reported positive topline results from the Phase 3b ENHANCE trial of BRIUMVI in relapsing multiple sclerosis.
The study met its primary endpoint, showing bioequivalent exposure between the approved Day 1/Day 15 initiation regimen and a new single 600 mg Day 1 infusion, with comparable safety and fewer infusion reactions in the single-infusion arm. A supplemental BLA filing is targeted for 2H-2026.